Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Zevra Therapeutics, with nine buy ratings and one hold rating. The average 12-month price target is $27.14, versus a recent share price of $12.01.
• Zevra reported quarterly EPS of $0.25, exceeding the $0.11 analyst consensus, while revenue of $39.66 million also topped expectations of $33.88 million.
• Institutional investors own 35.03% of the company, while insider ownership stands at 3.70%; director Corey Watton recently sold 12,300 shares at an average price of $11.25.

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $27.1429.

A number of research analysts have recently issued reports on ZVRA shares. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday, July 27th. Citizens Jmp raised their target price on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a "market outperform" rating in a research note on Thursday, August 6th. Guggenheim lowered their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Friday, August 7th. UBS Group reaffirmed a "buy" rating on shares of Zevra Therapeutics in a report on Thursday, August 20th. Finally, BTIG Research reduced their price target on Zevra Therapeutics from $27.00 to $24.00 and set a "buy" rating on the stock in a research report on Monday, July 27th.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $12.01 on Friday. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $15.03. The stock's 50-day moving average is $11.87 and its 200 day moving average is $11.11. The company has a market cap of $713.15 million, a P/E ratio of 13.05 and a beta of 0.95.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. The business had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. On average, analysts anticipate that Zevra Therapeutics will post 0.72 EPS for the current year.

Insiders Place Their Bets

In related news, Director Corey Watton sold 12,300 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the transaction, the director directly owned 1,800 shares of the company's stock, valued at $20,250. This represents a 87.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 3.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently modified their holdings of the business. Tidal Investments LLC acquired a new position in shares of Zevra Therapeutics during the second quarter valued at about $150,000. WINTON GROUP Ltd grew its position in Zevra Therapeutics by 49.0% during the 2nd quarter. WINTON GROUP Ltd now owns 24,335 shares of the company's stock worth $349,000 after purchasing an additional 8,001 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Zevra Therapeutics during the 2nd quarter worth approximately $28,000. California State Teachers Retirement System grew its position in Zevra Therapeutics by 271.5% during the 2nd quarter. California State Teachers Retirement System now owns 11,200 shares of the company's stock worth $161,000 after purchasing an additional 8,185 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in Zevra Therapeutics by 5.2% during the 2nd quarter. Wellington Management Group LLP now owns 164,538 shares of the company's stock valued at $2,359,000 after purchasing an additional 8,121 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.